Shanghai Fosun Pharmaceutical (Group) Co (HK:2196) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Shanghai Fosun Pharmaceutical has announced the acceptance of drug registration applications for two new chemical drugs developed by its subsidiaries. These drugs, Levofloxacin Injection and Cytarabine Injection, have been approved by the National Medical Products Administration, marking a significant step in the company’s pharmaceutical innovations. This development could potentially enhance Fosun Pharma’s market position and attract investor interest.
For further insights into HK:2196 stock, check out TipRanks’ Stock Analysis page.